FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310118196> ?p ?o ?g. }

• W4310118196 endingPage "5683" @default.
• W4310118196 startingPage "5682" @default.
• W4310118196 abstract "Background: Recently, direct oral anticoagulants (DOACs) have been investigated as an alternative to low-molecular-weight heparin (LMWH) for the treatment of cancer-associated venous thromboembolism (VTE). Apixaban, edoxaban, and rivaroxaban showed non-inferiority in preventing recurrent VTE compared with the dalteparin. However, it was reported higher risk of bleeding in gastrointestinal (GI) cancers in patients treated with edoxaban and rivaroxaban compared with dalteparin, but not with apixaban. It has been suggested that non-resected GI cancers have higher risk of bleeding than resected ones. The CAP study investigated apixaban as a treatment for cancer associated VTE (1). In this subanalysis, we aimed to investigate risk factors for bleedings and to find out if reducing the dose of apixaban influenced bleedings. Methods: The CAP study was a prospective, single-arm, interventional study conducted in Norway to assess the efficacy and safety of apixaban as a treatment for cancer-associated VTE. Patients received initially 7 days with 10 mg apixaban twice daily followed by 5 mg twice daily (full dose) from baseline to 6 months, and 2.5 mg twice daily (low dose) from 7 to 36 months. Bleedings were categorized as major bleedings or clinically relevant non-major bleedings (CRNMB). The combination of major bleedings and CRNMB is referred to as clinically relevant bleedings” (CRBs). We investigated the following risk factors for bleeding: age, gender, low BMI, metastasis, unresected tumor, low thrombocyte count, cancer type, low hemoglobin, and concomitant use of anti-platelet therapy. Odds ratios (OR) and 95% confidence intervals (CI) were calculated to assess the association between risk factors and bleedings. Results: Patient characteristics and bleeding events by type of cancer are shown in table 1. We found that CRBs were associated with high age (above 74 years old, OR 2.0, 95% CI 1.0-4.1), low BMI (below 21.7, OR 2.3, 95% CI 1.1-4.8), and low hemoglobin (below 10.5 for females, OR 2.8, 95% CI 1.1-7.3 and 11.1 for males, OR 3.3, 95% CI 1.3-8.4), during full dose apixaban treatment period. Having GI or urogenital cancer were not associated with CRB compared with other cancers. In general, patients with unresected cancers did not have more bleedings than resected cancers. However, unresected GI cancer had increased risk of bleeding (OR 3.4, 95% CI 1.0-11.6) compared with resected GI cancer. Within the group of urogenital cancer, resected cancers were apparently associated with bleeding (OR 11.1, 95% CI 1.3-94.0), although with a large confidence interval. We did not find any risk factors associated with CRB from 7-36 months except for having breast cancer (OR 3.2, 95% CI 1.0-10.0). The frequency of major bleeding events was higher in full-dose period compared to the low-dose period but the frequency of CRNMB was not influenced by the reduction in apixaban dose (figure 1). There was one fatal bleeding in the full-dose period. Conclusion: Risk factors for bleeding in treatment with full dose apixaban were high age, low BMI, low hemoglobin. Low dose apixaban apparently reduced major bleeding events, but not CRNMB. Reference: 1. Larsen TL, Garresori H, Brekke J, Enden T, Frøen H, Jacobsen EM, et al. Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up. J Thromb Haemost. 2022;20(5):1166-81. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310118196 created "2022-11-30" @default.
• W4310118196 creator A5000479422 @default.
• W4310118196 creator A5000653738 @default.
• W4310118196 creator A5013351073 @default.
• W4310118196 creator A5052927725 @default.
• W4310118196 date "2022-11-15" @default.
• W4310118196 modified "2023-09-27" @default.
• W4310118196 title "Bleedings in Cancer Patients Treated with Apixaban for Venous Thromboembolism" @default.
• W4310118196 doi "https://doi.org/10.1182/blood-2022-164857" @default.
• W4310118196 hasPublicationYear "2022" @default.
• W4310118196 type Work @default.
• W4310118196 citedByCount "0" @default.
• W4310118196 crossrefType "journal-article" @default.
• W4310118196 hasAuthorship W4310118196A5000479422 @default.
• W4310118196 hasAuthorship W4310118196A5000653738 @default.
• W4310118196 hasAuthorship W4310118196A5013351073 @default.
• W4310118196 hasAuthorship W4310118196A5052927725 @default.
• W4310118196 hasConcept C121608353 @default.
• W4310118196 hasConcept C126322002 @default.
• W4310118196 hasConcept C141071460 @default.
• W4310118196 hasConcept C156957248 @default.
• W4310118196 hasConcept C2776301958 @default.
• W4310118196 hasConcept C2778661090 @default.
• W4310118196 hasConcept C2779161974 @default.
• W4310118196 hasConcept C2780290652 @default.
• W4310118196 hasConcept C2780638905 @default.
• W4310118196 hasConcept C71924100 @default.
• W4310118196 hasConceptScore W4310118196C121608353 @default.
• W4310118196 hasConceptScore W4310118196C126322002 @default.
• W4310118196 hasConceptScore W4310118196C141071460 @default.
• W4310118196 hasConceptScore W4310118196C156957248 @default.
• W4310118196 hasConceptScore W4310118196C2776301958 @default.
• W4310118196 hasConceptScore W4310118196C2778661090 @default.
• W4310118196 hasConceptScore W4310118196C2779161974 @default.
• W4310118196 hasConceptScore W4310118196C2780290652 @default.
• W4310118196 hasConceptScore W4310118196C2780638905 @default.
• W4310118196 hasConceptScore W4310118196C71924100 @default.
• W4310118196 hasIssue "Supplement 1" @default.
• W4310118196 hasLocation W43101181961 @default.
• W4310118196 hasOpenAccess W4310118196 @default.
• W4310118196 hasPrimaryLocation W43101181961 @default.
• W4310118196 hasRelatedWork W2081941252 @default.
• W4310118196 hasRelatedWork W2083901189 @default.
• W4310118196 hasRelatedWork W2093259736 @default.
• W4310118196 hasRelatedWork W2116384196 @default.
• W4310118196 hasRelatedWork W2372279560 @default.
• W4310118196 hasRelatedWork W2741126211 @default.
• W4310118196 hasRelatedWork W2746504652 @default.
• W4310118196 hasRelatedWork W2945012027 @default.
• W4310118196 hasRelatedWork W2999402470 @default.
• W4310118196 hasRelatedWork W3191595415 @default.
• W4310118196 hasVolume "140" @default.
• W4310118196 isParatext "false" @default.
• W4310118196 isRetracted "false" @default.
• W4310118196 workType "article" @default.